Annual EBITDA
-$7.81 M
+$109.41 M+93.33%
31 December 2021
Summary:
Aerie Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$7.81 million, with the most recent change of +$109.41 million (+93.33%) on 31 December 2021. During the last 3 years, it has risen by +$109.41 million (+93.33%).AERI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$21.73 M
-$7.02 M-47.72%
30 September 2022
Summary:
Aerie Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$21.73 million, with the most recent change of -$7.02 million (-47.72%) on 30 September 2022.AERI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$3.07 M
+$934.00 K+23.30%
30 September 2022
Summary:
Aerie Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$3.07 million, with the most recent change of +$934.00 thousand (+23.30%) on 30 September 2022.AERI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AERI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +93.3% | +4.1% | +96.8% |
| 5 y5 years | +96.2% | +45.6% | +98.0% |
AERI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | at high | -134.3% | at high |
Aerie Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$21.73 M(+47.7%) | -$3.07 M(-23.3%) |
| June 2022 | - | -$14.71 M(-50.9%) | -$4.01 M(-66.3%) |
| Mar 2022 | - | -$29.95 M(-147.3%) | -$11.88 M(+47.5%) |
| Dec 2021 | -$7.81 M(-93.3%) | $63.33 M(-379.4%) | -$8.05 M(-91.6%) |
| Sept 2021 | - | -$22.67 M(+0.3%) | -$96.40 M(-1.7%) |
| June 2021 | - | -$22.59 M(-13.5%) | -$98.02 M(-9.9%) |
| Mar 2021 | - | -$26.13 M(+4.4%) | -$108.74 M(-7.2%) |
| Dec 2020 | -$117.22 M(-30.8%) | -$25.02 M(+3.0%) | -$117.22 M(-13.7%) |
| Sept 2020 | - | -$24.29 M(-27.1%) | -$135.88 M(-10.3%) |
| June 2020 | - | -$33.31 M(-3.8%) | -$151.56 M(-4.9%) |
| Mar 2020 | - | -$34.61 M(-20.8%) | -$159.41 M(-5.9%) |
| Dec 2019 | -$169.38 M(-17.6%) | -$43.68 M(+9.3%) | -$169.38 M(+10.2%) |
| Sept 2019 | - | -$39.96 M(-2.9%) | -$153.71 M(-22.3%) |
| June 2019 | - | -$41.16 M(-7.7%) | -$197.92 M(-6.0%) |
| Mar 2019 | - | -$44.57 M(+59.1%) | -$210.50 M(+2.4%) |
| Dec 2018 | -$205.65 M(+42.8%) | -$28.01 M(-66.7%) | -$205.65 M(-13.5%) |
| Sept 2018 | - | -$84.18 M(+56.6%) | -$237.88 M(+28.5%) |
| June 2018 | - | -$53.74 M(+35.3%) | -$185.11 M(+16.5%) |
| Mar 2018 | - | -$39.73 M(-34.0%) | -$158.84 M(+10.3%) |
| Dec 2017 | -$143.97 M | -$60.23 M(+91.8%) | -$143.97 M(+27.8%) |
| Sept 2017 | - | -$31.41 M(+14.3%) | -$112.64 M(+8.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$27.47 M(+10.5%) | -$104.17 M(+5.2%) |
| Mar 2017 | - | -$24.85 M(-14.0%) | -$99.01 M(+3.2%) |
| Dec 2016 | -$95.90 M(+34.2%) | -$28.91 M(+26.1%) | -$95.90 M(+10.6%) |
| Sept 2016 | - | -$22.93 M(+2.8%) | -$86.68 M(+7.1%) |
| June 2016 | - | -$22.32 M(+2.6%) | -$80.97 M(+5.7%) |
| Mar 2016 | - | -$21.75 M(+10.5%) | -$76.63 M(+7.2%) |
| Dec 2015 | -$71.48 M(+50.7%) | -$19.69 M(+14.3%) | -$71.48 M(+5.7%) |
| Sept 2015 | - | -$17.22 M(-4.2%) | -$67.64 M(+6.4%) |
| June 2015 | - | -$17.98 M(+8.3%) | -$63.55 M(+10.8%) |
| Mar 2015 | - | -$16.60 M(+4.7%) | -$57.37 M(+21.0%) |
| Dec 2014 | -$47.43 M(+73.8%) | -$15.85 M(+20.7%) | -$47.43 M(+15.9%) |
| Sept 2014 | - | -$13.13 M(+11.3%) | -$40.92 M(+10.5%) |
| June 2014 | - | -$11.80 M(+77.3%) | -$37.04 M(+21.6%) |
| Mar 2014 | - | -$6.66 M(-28.7%) | -$30.46 M(+11.6%) |
| Dec 2013 | -$27.29 M(+84.8%) | -$9.34 M(+0.9%) | -$27.29 M(+27.5%) |
| Sept 2013 | - | -$9.25 M(+77.3%) | -$21.41 M(+36.5%) |
| June 2013 | - | -$5.22 M(+49.9%) | -$15.69 M(+49.9%) |
| Mar 2013 | - | -$3.48 M(+0.9%) | -$10.47 M(+49.8%) |
| Dec 2012 | -$14.77 M(+15.9%) | -$3.45 M(-2.3%) | -$6.99 M(+97.7%) |
| Sept 2012 | - | -$3.53 M | -$3.53 M |
| Dec 2011 | -$12.74 M | - | - |
FAQ
- What is Aerie Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Aerie Pharmaceuticals?
- What is Aerie Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Aerie Pharmaceuticals?
- What is Aerie Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Aerie Pharmaceuticals?
What is Aerie Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AERI is -$7.81 M
What is the all time high annual EBITDA for Aerie Pharmaceuticals?
Aerie Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$7.81 M
What is Aerie Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AERI is -$21.73 M
What is the all time high quarterly EBITDA for Aerie Pharmaceuticals?
Aerie Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $63.33 M
What is Aerie Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AERI is -$3.07 M
What is the all time high TTM EBITDA for Aerie Pharmaceuticals?
Aerie Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$3.07 M